Follow TPIMS:

  • Facebook: tpims
  • Linked In: company/torrey-pines-institute-for-molecular-studies
  • Twitter: tpims
  • External Link: plus.google.com/101737409313074589710/posts
  Untitled Document Share

Eugene Levin

Eugene G. Levin TorreyPinesInstituteCA

Adjunct Member

858.597.3885 - phone
858.597.3804 - fax
This e-mail address is being protected from spambots. You need JavaScript enabled to view it




For 20 years, Dr. Levin held numerous positions at the Scripps Clinic and the Scripps Research Institute — Research Associate in the Scripps Clinic's Department of Immunology, Assistant Member in the Department of Molecular and Experimental Medicine, and then from 1990 — 1999, Associate Professor in the Department of Molecular and Experimental Medicine at TSRI. From 1999-2005, Dr. Levin was a Professor in the Vascular Biology Division at the La Jolla Institute for Molecular Medicine. In 2004, through his research on macular degeneration, Dr. Levin founded Motility Incorporated, San Diego, California and continues to serve as its President. He has been a member of Torrey Pines Institute since 2005.

For 20 years, Dr. Levin held numerous positions at the Scripps Clinic and the Scripps Research Institute — Research Associate in the Scripps Clinic's Department of Immunology, Assistant Member in the Department of Molecular and Experimental Medicine, and then from 1990 — 1999, Associate Professor in the Department of Molecular and Experimental Medicine at TSRI. From 1999-2005, Dr. Levin was a Professor in the Vascular Biology Division at the La Jolla Institute for Molecular Medicine. In 2004, through his research on macular degeneration, Dr. Levin founded Motility Incorporated, San Diego, California and continues to serve as its President. He has been a member of TPIMS since 2005.

Education

  • 1973 - 1977   Ph.D., Biochemistry, University of California, Irvine, CA
  • 1969 - 1971   M.S., Microbiology, Colorado State University, Fort Collins, CO
  • 1965 - 1969   B.S., Microbiology, Pennsylvania State University, University Park, PA

Positions

  • 2005 - present:  Member,  Torrey Pines Institute for Molecular Studies, San Diego CA
  • 2004 - presen:  President, Motility Inc, San Diego CA
  • 2000 - 2005:  Professor, La Jolla Institute for Molecular Medicine, San Diego CA
  • 1990 - 2000:  Associate Professor, Departments of Molecular and Experimental Medicine and Vascular Biology, The Scripps Research Institute, La Jolla, California
  • 1984 - 1990:  Assistant Member, Department of Molecular and Experimental Medicine, Scripps Research Institute, La Jolla, California
  • 1981 - 1983:  Research Associate, Department of Immunology, The Scripps Research Institute, La Jolla, California
  • 1977 - 1981:  Postdoctoral Research Fellow, Department of Immunology, The Scripps Research Institute, La Jolla, California

Honors and Awards

  • University of California Regents Fellowship, 1973-1974.
  • NIH Predoctoral Fellowship, 1974 — 1977.
  • Southern California Hemophilia Foundation Fellowship, 1977-1978.
  • American Heart Association, California Affiliate, Advanced Postdoctoral Fellowship, 1979 — 1982.
  • American Heart Association, Established Investigator Award, 1989 — 1994.

Selected Publications (10 of 62)

  1. Piotrowicz RS and EG Levin. 1997.  Baso-lateral membrane-associated heat shock protein 27 kDa and microfilament polymerization.  J Biol Chem,  272:25920-25927, 1997.
  2. Piotrowicz RS and Levin EG. Heat shock protein 27 kDa expression and phosphorylation regulates endothelial cell migration.  FASEB J, 12:1481-1490, 1998.
  3. Santell L, Marotti KR and Levin EG.  Targeting of tissue plasminogen activator into the regulated secretory pathway of neuroendocrine cells.  Brain Research, 816(1):258-265, 1998.
  4. Piotrowicz RS, Maher PA and EG Levin.  Dual Activities of 22-24 kDa Basic-Fibroblast Growth Factor: Inhibition of Migration and Stimulation of Proliferation. J Cell Physiol,178(2):144-153, 1999.
  5. Levin EG, Banka CL and Parry GCN.  Progressive and Transient Expression of Tissue Plasminogen Activator During Fetal Development.  Arterioscl Thromb Vasc Biol 20(6):1668-1674, 2000.
  6. Piotrowicz RS, L Ding, P Maher  and EG Levin.  Inhibition of cell migration by 24kD FGF-2 is dependent upon the estrogen receptor.  J Biol Chem 276:3963-70, 2001
  7. Ding, L., Donate F, Parry GCN, Maher PA, and Levin EG. Inhibition of cell migration and angiogenesis by the amino terminal end of 24kD basic fibroblast growth factor. J Biol Chem, 277:31056-31061, 2002
  8. Levin EG, Sikora L, Ding L, and Sriramarao P. Inhibition of tumor cell migration by a truncated form of 24kDa FGF-2 leads to suppression of tumor growth and angiogenesis in vivo. Am J Pathology, 164:1183-1190,2004
  9. Pham NL, Franzen A, Levin EG. NF1 regulatory element functions as a repressor of tissue plasminogen activator expression. Arterioscler Thromb Vasc Biol, 24(5):982-7, 2004.
  10. Levin E. Cancer Therapy Through Control of Cell Migration, Curr Cancer  Drug Targets. 7:505-18, 2005

Patents (5 of 7)

  1. Truncated 24kDa basic fibroblast growth factor - U.S. Patent No.:7432243 B2
  2. Truncated 24kDa basic fibroblast growth factor - U.S. Patent No.: 7629146 B2
  3. Truncated 24kDa basic fibroblast growth factor - U.S. Patent Application Serial No.: 12/604,577
  4. Australian Patent No.: 2003223506
  5. New Zealand Patent No.: 536040